Dimethylpentylone (bk-DMPEA / "dipentylone")
Dimethylpentylone (also sold as 'dipentylone'; a dimethylamino methylenedioxy pentanophenone cathinone) is a recent synthetic cathinone that surged in seized-drug surveillance from around 2022-2023, frequently mis-sold as MDMA or eutylone. It is one of the least-characterised cathinones in current circulation, with human pharmacology essentially unknown.
01 Overview
Dimethylpentylone emerged as a successor to eutylone in mis-sold 'ecstasy' and has been flagged repeatedly by early-warning systems and forensic laboratories. It is reported as a long-lasting stimulant with limited euphoria and delayed onset, features that drive redosing and prolonged insomnia, much like eutylone.
There is essentially no clinical or pharmacological literature specific to this compound beyond identification and toxicology notifications. Class hazards apply: cardiovascular strain, compulsive redosing, severe comedown with insomnia, and unconfirmed long-term neurotoxicity.
02 Mechanism
Presumed monoamine releaser/reuptake inhibitor by analogy to related methylenedioxy pentanophenone cathinones; the tertiary dimethylamino group is associated with longer, more stimulant-dominant effects.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Light | 25–70 mg | Insufflated | Faster onset; harsh nasally. |
| Light | 40–90 mg | Oral | Anecdotal; delayed onset risks premature redosing. No clinical data. |
| Common | 90–175 mg | Oral | Long duration; redosing worsens insomnia and comedown. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| StimulationLong-lasting energy and wakefulness, more stimulating than euphoric. | Anecdotal | ||
| Mild sociabilitySome entactogenic character reported but weaker than MDMA. | Anecdotal | ||
| Compulsive redosingDelayed onset and long duration promote redosing and insomnia. | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Prolonged insomnia and severe comedownLong duration causes extended wakefulness followed by low mood, anxiety and fatigue. | Moderate | Very common | Anecdotal | |
| Long-term neurotoxicity (unknown)No human data; long-term effects unestablished for this very new compound. | Moderate | Unknown | Unconfirmed | |
| Cardiovascular strainTachycardia, palpitations and hypertension expected by class analogy and reported anecdotally. | Severe | Common | Anecdotal |